Catalyst Pharmaceuticals, Inc.
CPRX
Hisse Senetlerindeki Sıralama
#4178
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Hisse Fiyatı
$31.49
Son senkronizasyon: 2026-07-21
Piyasa Değeri
$3.85B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
46.94%
Ülke
US
Ticaret Catalyst Pharmaceuticals, Inc. (CPRX)
Kategori
Healthcare
Catalyst Pharmaceuticals, Inc. (CPRX) için gelir
Mar 2026 itibarıyla gelir TTM: $596.96M
Catalyst Pharmaceuticals, Inc. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $596.96M'dir. 2023 yılında şirketin geliri $398.20M önceki yıla göre artış 2022 yılındaki $214.20M gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Catalyst Pharmaceuticals, Inc. için 2002 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $596.96M | 21.40% |
| 2024 | $491.73M | 23.49% |
| 2023 | $398.20M | 85.90% |
| 2022 | $214.20M | 52.10% |
| 2021 | $140.83M | 18.27% |
| 2020 | $119.07M | 16.39% |
| 2019 | $102.31M | 20,361.20% |
| 2018 | $500.00K | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | -100.00% |
| 2010 | $488.96K | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| $12.62B | 2,014.77% |
US
|
|
| $2.23B | 273.23% |
US
|
|
| $15.74B | 2,537.43% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 908.66% |
NL
|
